Group 4A: HER2+ Breast Cancer; HR+ Breast Cancer; QOL & Survivorship



Thursday, Dec 15
10:00 am – 11:30 am Eastern Time (US/New York)



Poster #P3-02-02

Real-world time-to-treatment discontinuation in hormone-receptor-positive metastatic breast cancer patients following CDK4/6 inhibitor treatment, based on observational data collected through patient-partnered research

Poster author Ariel Carmeli, M.S. will attend this session

Poster #P4-01-37:

Discontinuation of HER2+ targeted therapy among cancer survivors with metastatic HER2+ breast cancer: A case report

Mentor: Cathy Knowles

My name is Cathy Knowles and I live in Pensacola Florida with my husband and two dogs. I was diagnosed de novo stage 4 with metastasis to my liver in January of 2017. I am ER+HER2+ and still on my first line of treatment. I retired in 2019 after spending most of my career as a research associate/lab manager in several basic biomedical research programs. In addition to acting as a mentor for GRASP, I am a peer mentor with Project Life, completed the Hear My Voice advocacy training program with Living Beyond Breast Cancer (LBBC) in 2020 and am currently serving as a patient advocate reviewer with Metavivor. I am passionate about helping others learn about MBC.

Scientist: Diogo Martins Branco, M.D.

Diogo has been a board-certified medical oncologist since March 2019. During his oncology fellowship training, he completed a Master in Palliative Care from King’s College London. His research project was dedicated to models of care at the end-of-life. After completing his medical oncology fellowship, he began a Fellowship of Scientific Communication at Champalimaud Foundation in Lisbon, Portugal where he had close contact with patient advocacy groups which provided him with a better understanding of the patient perspective in translational cancer research.

Since January 2021, he has been working in Brussels, Belgium, as a medical research fellow at the Academic Trials Promoting Team and Clinical Trials Support Unit of Institut Jules Bordet. Here he works in the conceptualization, design, protocol development, implementation, and medical monitoring of clinical trials, both investigator-initiated, and industry sponsored as academic partners.

Twitter: @DMBranco